Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02155504
Other study ID # 3700-CL-0001
Secondary ID 2013-005018-36
Status Completed
Phase Phase 1
First received May 28, 2014
Last updated October 29, 2014
Start date May 2014
Est. completion date October 2014

Study information

Verified date October 2014
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of ASP3700 in healthy male subjects. This study will also explore the effect of itraconazole (another drug) on the PK of ASP3700, as well as to evaluate the safety and tolerability of ASP3700 alone and in combination with itraconazole in healthy male subjects.


Description:

This study consists of 2 parts: Part 1 is a single ascending dose study where subjects will receive either ASP3700 or matching placebo; Part 2 is a drug-drug interaction (DDI) open-label, crossover study comprised of 1 sequence with 2 investigational periods where subjects will receive ASP3700 alone and in combination with itraconazole.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Subject has a body mass index range of 18.5 - 30.0 kg/m2. The subject weighs at least 50 kg.

- Subject and his female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the clinical study period and for 90 days after the final study drug administration.

- Subject must not donate sperm starting at screening and throughout the clinical study period and for 90 days after the final study drug administration.

Exclusion Criteria:

- Subject has a known or suspected hypersensitivity to ASP3700 (parts 1 and 2) or itraconazole (part 2 only) or significant adverse reactions to historical cannabinoid use or any components of the formulations used.

- Subject has any of the liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transaminase, total bilirubin [TBL]) above the upper limit of normal (ULN). In such a case the assessment may be repeated once (upon admission to the clinical unit).

- Subject has a history of a suicide attempt or suicidal behavior. Any recent suicidal ideation within the last 3 months or who are at significant risk to commit suicide, as judged by the Investigator using the C-SSRS (a level of 4 or 5) at screening or upon admission to the clinical unit.

- Subject has any clinically significant abnormality following the Investigator's review of the physical examination, ECG and clinical study protocol-defined clinical laboratory tests at screening or upon admission to the clinical unit.

- Subject has a pulse rate < 40 or > 90 beats per minute; mean SBP > 140 mmHg; mean DBP > 90 mmHg (vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse rate will be measured automatically) upon admission to the clinical unit.

- Subject has a mean corrected QT interval using Fridericia's formula (QTcF) interval > 430 ms at day -1. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken.

- Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.

- Subject has a history of drinking more than 21 units of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit.

- Subject has consumed grapefruit, grapefruit-containing products or Seville orange-containing products within 72 hours prior to admission to the clinical unit.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
ASP3700
oral
itraconazole
oral
Placebo
oral

Locations

Country Name City State
United Kingdom Parexel Early Phase Clinical Unit Harrow

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Europe B.V.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety as assessed by adverse events (Part 1) up to end of study visit (up to 16 days) No
Primary Safety as assessed by vital signs (Part 1) up to end of study visit (up to 16 days) No
Primary Safety as assessed by laboratory tests (Part 1) Laboratory tests includes the measurement of sex-hormone related biomarkers and exploratory renal biomarkers. up to end of study visit (up to 16 days) No
Primary Safety as assessed by electrocardiogram (ECG) measurements (Part 1) ECG measurements include routine 12-lead ECG, continuous cardiac monitoring (Holter ECG) and real-time cardiac monitoring (ECG telemetry) up to end of study visit (up to 16 days) No
Primary Safety as assessed by Bond and Lader VAS (Part 1) visual analogue scale (VAS) Up to Day 2 No
Primary Safety as assessed by C-SSRS (Part 1) Columbia - Suicide Severity Rating Scale (C-SSRS) Up to end of study visit (up to 16 days) No
Primary Safety as assessed by ARCI-49 (Part 1) Addiction Research Center Inventory (ARCI)-49 (49-item) Up to Day 2 No
Primary Pharmacokinetic parameter of itraconazole (plasma): Ctrough (Part 2) Concentration immediately prior to dosing at multiple dosing Days 3-13 No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): AUCinf (Part 2) Area under the concentration-time curve from time of dosing extrapolated to time infinity (AUCinf) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): AUCinf (%extrap) (Part 2) Percentage of AUCinf due to extrapolation from tlast to time infinity (AUCinf [%extrap]) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): AUClast (Part 2) Area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): Cmax (Part 2) Maximum concentration (Cmax) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma):?z (Part 2) Terminal elimination rate constant (?z) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): MRT (Part 2) Mean residence time (MRT) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): tlag (Part 2) Time prior to the time corresponding to the first measurable (nonzero) concentration (tlag) Day 1 (period 1 and 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): tmax (Part 2) Time of maximum concentration (tmax) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): t1/2 (Part 2) Terminal elimination half-life (t1/2) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): Vz/F (Part 2) Apparent volume of distribution during the terminal elimination phase after extravascular dosing (Vz/F) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aelast (Part 2) Cumulative amount of study drug excreted into urine from time of dosing up to the collection time of the last measurable concentration (Aelast) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aeinf (Part 2) Cumulative amount of study drug excreted into urine from time of dosing extrapolated to time infinity (Aeinf) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aelast% (Part 2) Percentage of study drug excreted into urine from the time of dosing up to the collection time of the last measurable concentration (Aelast%) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aeinf% (Part 2) Percentage of study drug excreted into urine from time of dosing extrapolated to time infinity (Aeinf%) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): CLR (Part 2) Renal clearance (CLR) Days 1-7 (period 1) and Days 1-13 (period 2) No
Primary Safety as assessed by orthostatic evaluation (or blood pressure change in orthostatic challenge test) (Part 1) Up to Day 7 No
Secondary Composite of pharmacokinetics of ASP3700: AUCinf, AUCinf(%extrap), AUClast, Cmax, CL/F, ?z, MRT, tlag, tmax, t½, Vz/F (plasma) (Part 1) up to Day 7 No
Secondary Title: Composite of pharmacokinetics of ASP3700: Aelast, Aeinf, Aelast%, Aeinf%, CLR (urine) (Part 1) up to Day 7 No
Secondary Safety as assessed by adverse events, vital signs, orthostatic evaluation, laboratory tests, ECG measurements, C-SSRS, Bond & Lader VAS, ARCI-49 (Part 2) Days 1-7 (period 1) and Days 1-13 (period 2) and at end of study visit (up to 22 days) No
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1